Biomerica’s real-world inFoods® IBS data showed that 59.4% of patients achieved at least 30% abdominal pain reduction and 68.1% achieved similar bloating relief, using an FDA-recognized responder endpoint. The company also obtained a $300 national Medicare payment rate for the test effective January 1, 2026, and is working with its lab partner to secure coverage from the Medicare Administrative Contractor.

European revenue rose 45% year-over-year to $287,000, reflecting growing demand for Biomerica’s products on the continent. hp+detect™ received UK MHRA registration post-quarter and landed its first commercial European lab order from a large clinical laboratory chain, positioning the test for broader EU adoption and recurring sales.

Net sales for the third quarter were $987,000, down from $1.12 million in the prior‐year period, driven by variable contract manufacturing activity despite growth in inFoods® IBS and a 16% increase in over-the-counter products. For the nine months ended February 28, sales totaled $3.58 million versus $4.56 million, with gross margin decreasing to approximately 13% from 15%.

Research and development expenses for the year‐to‐date declined 24% to $583,000, reflecting completion of key development phases for hp+detect™ and inFoods® IBS. Operating expenses fell slightly year-over-year, contributing to a nine-month net loss improvement to $2.63 million from $3.43 million, and net loss per share sharpened by 37% to $(0.92).